hameln pharma ApS Financials, key figures and credit report
Gross profit 10 300.2 kDKK FY 2025 +50.2% vs 2024
EBIT 10 300.2 kDKK FY 2025 +50.2% vs 2024
Net debt -6 915.6 kDKK FY 2025 -81.2% vs 2024
Quick ratio 4.0 FY 2025 +2.1 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 1 874.15 | 2 613.04 | 3 130.28 | 6 856.81 | 10 300.18 |
| EBIT | 1 874.15 | 2 613.04 | 3 130.28 | 6 856.81 | 10 300.18 |
| Other financial income | 2.98 | 13.62 | 142.04 | 173.85 | |
| Other financial expenses | -49.98 | - 161.69 | - 161.10 | - 140.25 | - 127.46 |
| Pre-tax profit | 1 824.17 | 2 454.33 | 2 982.79 | 6 858.60 | 10 346.56 |
| Income taxes | - 407.59 | - 544.22 | - 658.24 | -1 569.93 | -2 295.96 |
| Net earnings | 1 416.58 | 1 910.11 | 2 324.55 | 5 288.67 | 8 050.60 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Finished products/goods | 3 164.33 | 3 525.70 | 6 093.64 | 6 326.49 | 8 141.64 |
| Inventories total | 3 164.33 | 3 525.70 | 6 093.64 | 6 326.49 | 8 141.64 |
| Current trade debtors | 1 219.05 | 2 822.24 | 6 969.36 | 4 755.67 | 6 745.79 |
| Current amounts owed by group member comp. | 41.20 | 47.00 | |||
| Prepayments and accrued income | 107.84 | 133.49 | 149.73 | 149.84 | 364.67 |
| Current other receivables | 9.43 | 408.84 | 408.39 | 408.42 | |
| Current deferred tax assets | 49.41 | 225.78 | |||
| Short term receivables total | 1 376.29 | 3 190.93 | 7 527.93 | 5 355.10 | 7 565.88 |
| Cash and bank deposits | 666.86 | 2 718.63 | 1 912.68 | 6 946.86 | 8 661.09 |
| Cash and cash equivalents | 666.86 | 2 718.63 | 1 912.68 | 6 946.86 | 8 661.09 |
| Balance sheet total (assets) | 5 207.49 | 9 435.26 | 15 534.25 | 18 628.45 | 24 368.60 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 50.00 | 50.00 | 50.00 | 50.00 | 50.00 |
| Shares repurchased | 6 500.00 | ||||
| Retained earnings | 1 781.03 | 3 083.85 | 5 001.96 | 6 958.53 | 5 734.17 |
| Profit of the financial year | 1 416.58 | 1 910.11 | 2 324.55 | 5 288.67 | 8 050.60 |
| Shareholders equity total | 3 247.61 | 5 043.96 | 7 376.51 | 12 297.20 | 20 334.77 |
| Non-current liabilities total | |||||
| Current trade creditors | 292.10 | 1 354.25 | 2 912.89 | 712.92 | 985.32 |
| Current owed to group member | 1 433.76 | 2 417.08 | 3 124.59 | 3 130.48 | 1 745.47 |
| Short-term deferred tax liabilities | 902.75 | 935.83 | 95.96 | ||
| Other non-interest bearing current liabilities | 234.02 | 619.96 | 1 217.51 | 1 552.02 | 1 207.07 |
| Current liabilities total | 1 959.88 | 4 391.30 | 8 157.74 | 6 331.25 | 4 033.82 |
| Balance sheet total (liabilities) | 5 207.49 | 9 435.26 | 15 534.25 | 18 628.45 | 24 368.60 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated